Leveraging AI to predict patients at risk of early treatment discontinuation*

1 Pages

A biopharma observed shorter therapy duration on its lupus drug versus competitors. IQVIA built AI/ML models predicting discontinuation risk and linked 900 potentially non-adherent patients to managing physicians. Field reps received real-time alerts, enabling timely intervention within narrow windows of opportunity. The model improved outreach precision, focusing on 25% of HCPs managing high-risk patients. This approach supported counseling, improved adherence, and strengthened brand competitiveness by preventing early discontinuation and improving patient outcomes.

Join for free to read

Report Building Trust in Healthcare AI - Perspectives from Patients and…

White Paper EARLY DETECTION OF DIABETIC RETINOPATHY

Report A new era of precision medicine

White Paper THE HOLY GRAIL OF WINNING HCP ATTENTION

More from IQVIA

White Paper USING AI & MACHINE LEARNING TO DRIVE COMMERCIAL SUCCESS IN THE EU

Case Study Achieving early treatment adoption with predictive modeling

White Paper Digital Twins in Healthcare: Unlocking the Future of…

White Paper Generative AI: The Future of Pharmacovigilance

Case Study

Leveraging AI to predict patients at risk of early treatment discontinuation*

Leveraging AI to predict patients at risk of early treatment discontinuation*

You Might Also Like

More from IQVIA